A
Arcutis Biotherapeutics, Inc. (ARQT)
NMS – Real vaqt narxi. Valyuta: USD
20.69
-0.55 (-2.59%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
20.69
-0.55 (-2.59%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Arcutis Biotherapeutics, Inc., biofarmatsevtika kompaniyasi, dermatologik kasalliklarni davolashni ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning asosiy mahsuloti ZORYVE bo'lib, bu blyashka psoriaz va atopik dermatitni davolash uchun mo'ljallangan roflumilastli topikal kremdir. Shuningdek, u seboreik dermatit, bosh va tana psoriazini davolash uchun ZORYVE ko'pigi; CD200 retseptorining kuchli va yuqori selektiv tekshiruv agonisti bo'lgan ARQ-234 fuzion proteinini ishlab chiqadi. Kompaniya ilgari Arcutis, Inc. nomi bilan tanilgan va 2019-yil oktabr oyida Arcutis Biotherapeutics, Inc. nomini olgan. Arcutis Biotherapeutics, Inc. 2016-yilda ro'yxatga olingan va shtab-kvartirasi Kaliforniyaning Westlake Village shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder & Director Emeritus |
| Dr. Patrick E. Burnett M.D., Ph.D. | Executive VP & Chief Medical Officer |
| Mr. Brian Schoelkopf | Head of Investor Relations |
| Mr. Larry Todd Edwards | Executive VP & Chief Commercial Officer |
| Mr. Masaru Matsuda Esq., J.D. | Executive VP, Chief Legal Officer & Corporate Secretary |
| Mr. Rajvir Madan | Chief Digital & Technology Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 10-Q | arqt-20260331.htm |
| 2026-04-21 | S-8 | arcutiss-8xapril2026.htm |
| 2026-02-25 | S-8 | arcutiss-8xfebruary2026.htm |
| 2025-12-08 | 8-K | arqt-20251203.htm |
| 2025-10-28 | 10-Q | arqt-20250930.htm |
| 2025-08-06 | 10-Q | arqt-20250630.htm |
| 2025-06-17 | 8-K | arqt-20250612.htm |
| 2025-05-06 | 8-K | arqt-20250506.htm |
| 2025-05-06 | 10-Q | arqt-20250331.htm |
| 2025-04-29 | DEF 14A | arqt-20250429.htm |
| Mr. Steve Arias | Vice President of Compliance & Privacy |
| Mr. Todd Franklin Watanabe M.A. | President, CEO & Director |
| Ms. Amanda Sheldon | Head of Corporate Communications |
| Ms. Latha Vairavan | Senior VP & Chief Financial Officer |